Notice of Two Year Exclusivity Period; DAYPRORegister Oxaprozin
保存版の掲載情報です。最新の営業状況・料金・利用条件は出典をご確認ください。
保存されている情報
The Patent and Trademark Office has received notification from G. D. Searle & Co. that it claims entitlement under section 2105 of the FDA Export Reform and Enhancement Act of 1996 (Chapter 1A of Pub. L. No. 104-134) for its drug product DAYPRO oxaprozin.
- Current entry point
- www.federalregister.gov/documents/1996/05/22/96-12882/notice-of-two-year-exclusivity-period-dayproregister-oxaprozin (permanent link in the Federal Register, verified 2026-09-30)
- Legacy system and where it moved
- No legacy system name mention in title or summary )
- Fee
- No fee mention in title or summary )
- What you need (account or API key)
- No account or key mention in title or summary )
- Published
- 1996-05-22
- Document type
- Notice
原データ更新日：2026-10-06
保存版に記録された日付です。今回の実装・デプロイ日ではありません。